Salarius Pharmaceuticals (SLRX) Institutional Ownership $1.45 -0.03 (-2.03%) (As of 11/4/2024 ET) Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Salarius Pharmaceuticals (NASDAQ:SLRX)CurrentInstitutional OwnershipPercentage11.88%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$607.18KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$858.18K Get SLRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Salarius Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SLRX Institutional Buying and Selling by Quarter Ad Porter & CompanyRigged election? Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. Watch this video, it is being taken down Monday night Salarius Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2024Armistice Capital LLC22,750$54K0.0%-72.9%3.811% 2/13/2024Armistice Capital LLC88,000$57K0.0%-60.9%2.234% 11/15/2023Armistice Capital LLC225,000$148K0.0%+105.2%5.711% 11/15/2021HighTower Advisors LLC26,000$26K0.0%N/A0.058% 11/9/2021BlackRock Inc.116,309$119K0.0%-13.7%0.260% 8/25/2021Marshall Wace LLP174,474$185K0.0%+29.6%0.390% Get the Latest News and Ratings for SLRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/17/2021 X Square Capital LLC100,458$106K0.1%-39.4%0.224% 8/16/2021Maven Securities LTD1,316,205$1.37M0.1%-31.7%2.939% 8/16/2021State Street Corp142,552$151K0.0%N/A0.318% 8/16/2021Sabby Management LLC249,033$264K0.0%-6.7%0.556% 8/16/2021Marshall Wace LLP174,474$185K0.0%+29.6%0.390% 8/13/2021Northern Trust Corp65,022$69K0.0%+25.9%0.145% 8/13/2021Geode Capital Management LLC277,035$293K0.0%+124.4%0.619% 8/13/2021Vanguard Group Inc.1,544,724$1.64M0.0%+8.7%3.450% 8/12/2021Dimensional Fund Advisors LP36,634$39K0.0%-40.8%0.082% 5/19/2021Worth Venture Partners LLC424,800$629K0.3%+17.8%0.949% 5/18/2021Millennium Management LLC28,675$42K0.0%+40.5%0.064% 5/18/2021Silverarc Capital Management LLC1,992,181$2.95M1.6%N/A4.450% 5/14/2021Dimensional Fund Advisors LP61,839$92K0.0%N/A0.138% 5/13/2021Renaissance Technologies LLC237,601$352K0.0%N/A0.531% 5/13/2021Kepos Capital LP548,054$811K0.1%+338.4%1.225% 5/13/2021 X Square Capital LLC165,708$245K0.1%+186.4%0.370% 5/12/2021Northern Trust Corp51,648$76K0.0%+248.6%0.115% 5/12/2021Geode Capital Management LLC123,461$182K0.0%+573.5%0.276% 5/12/2021Granite Point Capital Management L.P.1,563,561$2.31M0.1%N/A3.495% 5/6/2021 Meitav Dash Investments Ltd.52,000$77K0.0%N/A0.116% 5/6/2021Altium Capital Management LP1,250,110$1.85M0.5%N/A2.795% 3/26/2021Susquehanna International Group LLP33,320$30K0.0%N/A0.074% 2/17/2021Worth Venture Partners LLC360,556$328K0.3%+39.6%1.514% 2/16/2021Squarepoint Ops LLC101,682$93K0.0%+765.5%0.427% (Data available from 1/1/2016 forward) SLRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SLRX shares? During the previous two years, the following institutional investors and hedge funds held shares of Salarius Pharmaceuticals shares: Armistice Capital LLC ($54K).Learn more on SLRX's institutional investors. What percentage of Salarius Pharmaceuticals stock is owned by institutional investors? 11.88% of Salarius Pharmaceuticals stock is owned by institutional investors. Learn more on SLRX's institutional investor holdings. Which institutional investors have been buying Salarius Pharmaceuticals stock? The following institutional investors have purchased Salarius Pharmaceuticals stock in the last 24 months: Armistice Capital LLC ($115.36K). How much institutional buying is happening at Salarius Pharmaceuticals? Institutional investors have bought a total of 115,364 shares in the last 24 months. This purchase volume represents approximately $607.18K in transactions. Which Salarius Pharmaceuticals major shareholders have been selling company stock? The following institutional investors have sold Salarius Pharmaceuticals stock in the last 24 months: Armistice Capital LLC ($198.25K). How much institutional selling is happening at Salarius Pharmaceuticals? Institutional investors have sold a total of 198,250 shares in the last 24 months. This volume of shares sold represents approximately $858.18K in transactions. Related Companies IMCC Institutional Ownership HOTH Institutional Ownership ATNF Institutional Ownership VCNX Institutional Ownership CHRO Institutional Ownership ENSC Institutional Ownership RNAZ Institutional Ownership MYMD Institutional Ownership SBFM Institutional Ownership PCSA Institutional Ownership This page (NASDAQ:SLRX) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
